Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

This study evaluated the ocular surface tolerability of the prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution 0.005% (Xalatan®) in patients previously treated with Xalatan® who have open-angle glaucoma or ocular hypertension.

Inclusion Criteria:

• Diagnosis of ocular hypertension or open-angle glaucoma in at least 1 eye requiring treatment with an anti-glaucoma/ocular hypertensive medication
• Best corrected visual acuity score of 20/100 or better in both eyes
• Females on birth control pills must be on same type of pill and dose for at least 3 month

Exclusion Criteria:

• Use of Lumigan® 0.01%/Lumigan® RC, Lumigan®, Travatan® or Travatan Z® within 6 months
• History of or active ocular infection/inflammation (eg, uveitis)
• Punctal plug use
• Required use of ocular medications during the study other than study medication (intermittent use of certain types artificial tears acceptable)
• Intraocular surgery or glaucoma laser surgery in study eye(s) within 3 months
• History of corneal refractive laser surgery (eg, LASIK, LASEK) in study eye(s)
• Planned contact lens wear during study